AnaptysBio Insider Sells $540,000 in Stock

Eric Loumeau, an insider at the biotech company, reduced his stake by 43.79%.

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of the company's stock for a total transaction value of $540,000. The sale represented a 43.79% decrease in Loumeau's position, leaving him with 12,835 shares valued at approximately $693,090.

Why it matters

Insider transactions, especially large sales, can provide insights into management's views on a company's prospects. Loumeau's significant reduction in his AnaptysBio holdings may signal concerns about the company's future performance or a desire to diversify his personal investments.

The details

The stock sale took place on February 11, 2026 at an average price of $54 per share. Loumeau is an insider at AnaptysBio, a clinical-stage biotechnology company focused on developing therapeutic antibody products for immunology and inflammation.

  • The stock sale occurred on February 11, 2026.

The players

Eric Loumeau

An insider at AnaptysBio, Inc. who sold 10,000 shares of the company's stock.

AnaptysBio, Inc.

A clinical-stage biotechnology company focused on developing therapeutic antibody products for immunology and inflammation.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This insider sale by an AnaptysBio executive could signal concerns about the company's future prospects, though more information would be needed to fully understand the motivations behind the transaction.